A New Era in Cancer Treatment; First Custom 'Melanoma' Vaccine Injected in Britain

The first custom mRNA-based vaccine for patients with melanoma, the deadliest skin cancer in Britain, is currently undergoing trials. A 52-year-old man, who had a cancerous tumor removed from his scalp last year, received the first custom melanoma vaccine developed by Merck and Moderna. This vaccine helps the immune system identify and eliminate other cancer cells, preventing the cancer from returning. The term 'custom' means that it is designed specifically for the patient receiving it and may not be effective for the next patient. The structure of the vaccine is tailored to the specific genetics of the patient's tumor and trains their immune system to produce antibodies to attack the antigens or pathogens of cancer cells. To design this custom treatment, a tumor sample is taken from the patient, and its DNA is sequenced, with artificial intelligence playing a role in this process. Custom vaccines open a new chapter in cancer treatment, allowing patients to move away from therapies like chemotherapy, which also harm healthy tissues and have numerous side effects, towards methods designed specifically for their type of cancer, which have fewer side effects. Phase II trials of this custom vaccine have shown that the likelihood of death or cancer recurrence after three years in high-risk melanoma patients who received the vaccine in combination with the immunotherapy drug Keytruda is half that of those who only received Keytruda. This novel cancer treatment method is also being tested for lung, liver, and kidney cancers. The production of mRNA and its injection into the body has been around for over thirty years. Vaccine development typically takes ten to fifteen years, but the COVID-19 pandemic accelerated the vaccine production process, and thanks to previous cancer research, it took just over a year. This has encouraged researchers to continue producing these vaccines for the treatment and prevention of other diseases, including cancer. There are two types of cancer prevention vaccines approved by the U.S. Food and Drug Administration; the HPV vaccine, which protects against the human papillomavirus (HPV). If this virus remains in the body for a long time, it can lead to certain types of cancer. The other vaccine is for hepatitis B, which protects against a virus that can cause liver cancer. Vaccines that treat cancer utilize a therapeutic method called immunotherapy, which strengthens and trains the immune system to fight cancer. Doctors administer therapeutic vaccines to cancer patients to eliminate any cancer cells that remain in the body after treatment or to prevent tumor growth or spread. This report utilized sources such as BBC Global and Cancer.net.